National Academy of Agricultural Sciences (NAAS)
 |
PRINT ISSN : 2319-7692 Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Increasing drug resistance due to the production of AmpC β-lactamases and Extended spectrum β-lactamases (ESBLs) is an increasing cause of concern as it has left the clinicians with limited therapeutic options. Aims were detection of AmpC β lactamase in E. coli an comparison of the two phenotypic tests- AmpC disk test and Inhibitor based test using phenyl boronic acid. A total of 156 E. coli isolates from various clinical samples were collected for the study. These isolates were further subjected to ESBL detection by disc diffusion test, screening for AmpC β-lactamases by cefoxitin disc and confirmation of AmpC β-lactamases by AmpC disc test and Inhibitor based test using phenyl boronic acid. Statustical analysis done by Chi-Square test and Fisher’s Exact test. AmpC screening detected 68 isolates as presumptive AmpC producers, of which 82.4% were confirmed to be true AmpC producers by confirmatory tests. Phenotypic confirmation by AmpC disc test and Inhibitor based test detected 20.5% and 35.9% isolates respectively as AmpC producers. Coexistence of AmpC with ESBL was seen among 32(20.5%) isolates. Pure AmpC producers were 15.4%. Pure AmpC producers as well as co-producers of ESBL and AmpC showed multidrug resistance. Pure AmpC producers showed 100% sensitivity to cefepime and imipenem while co-producers showed only 25% sensitivity to cefepime and 87.5% sensitivity to imipenem. The prevalence of AmpC producers among E. coli in our study was 35.9%. Pure AmpC producers are 100% susceptible to cefepime and imipenem. The Inhibitor based test is a simple, efficient and better test for the detection of AmpC production.
 |
 |
 |
 |
 |
